Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-29
2011-03-29
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07915218
ABSTRACT:
A system for expressing antigenic polypeptides in oligomeric form fuses the antigenic polypeptide to an oligomerisation polypeptide such that the oligomerisation polypeptide can interact with other oligomerisation polypeptides and bring multiple copies of the antigenic polypeptide into close proximity in the form of an oligomer. Expressing the polypeptides in oligomeric form in this way can improve their immunogenicity compared to a monomeric form.
REFERENCES:
patent: 6716429 (2004-04-01), Sodroski et al.
patent: 1 365 027 (2003-11-01), None
patent: WO 96/23881 (1996-08-01), None
Roggenkamp et al. Jul. 2003; Molecular analysis of transport and oligomerization of theYersinia enterocoliticaadhesin YadA. J. Bacteriol. 185(13): 3735-3744.
Comanducci, et al. 2002; NadA, a novel vaccine candidate ofNeisseria meningitides. J. Exp. Med. 195(11): 1445-1454.
Collins, P. “O Glycosylation of Glycoprotein G of Human Respiratory Syncytial Virus Is Specified within the Divergent Ectodomain,” Journal of Virology, 64(8): 4007-4012 (1990).
Liu, S. et al. “Cell Surface Tumor Endothelium Market 8 Cytoplasmic Tail-independent Anthrax Toxin Binding . . . ” The Journal of Biological Chemistry, 278(7): 5227-5234 (2003).
Capecchi, B. et al. “The Genome Revolution in Vaccine Research,” Curr Issues Mol Biol, 6: 17-28 (2004).
Hoiczyk, E. et al. “Structure and sequence analysis ofYersiniaYadA andMoraxellaUspAs reveal a novel class of . . . ” The EMBO Journal, vol. 19, No. 22, pp. 5989-5999 (2000).
Capecchi Barbara
Masignani Vega
Rappuoli Rino
Scarselli Maria
Carlson Karen Cochrane
Lee Helen
Littlefield Otis
Novartis AG
LandOfFree
Polypeptides for oligomeric assembly of antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides for oligomeric assembly of antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides for oligomeric assembly of antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2768554